SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of tradipitant for motion sickness, marking the first new treatment in decades. This milestone, combined with promising Phase 2 data showing tradipitant's efficacy in reducing GLP-1 induced nausea and vomiting, has ignited widespread community discussion about its significant potential in a rapidly expanding market. Investors are also keenly anticipating upcoming regulatory decisions for other pipeline candidates, fueling speculation about substantial growth and future acquisition interest.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is trending due to its recent loan agreement, which aims to secure capital without immediate equity dilution, and the planned distribution of a "Dream Bowl 2026 Meme Coin" dividend tied to its Datavault AI partnership. Community sentiment is highly polarized: many foresee a significant short squeeze and value creation from tokenization and potential asset sales, while a vocal segment views these developments as further distractions by a management team perceived as eroding shareholder value. The broader context involves the company's foray into AI-driven Real-World Asset tokenization, alongside ongoing scrutiny of its core biotech pipeline.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending following the recent FDA approval of FUROSCIX for pediatric use and new patents issued for its ReadyFlow Autoinjector, which the community views as a significant advancement for at-home fluid management. While optimism surrounds these developments and the anticipated Afrezza launch in India, a persistent debate centers on current management's ability to translate product success into substantial long-term shareholder value.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amid notable Bitcoin volatility and a mixed outlook driven by fluctuating ETF inflows and the impending Bank of Japan rate decision. The community is sharply divided between those anticipating a prolonged 'crypto winter' and others who see the current dips as a prime 'buy the dip' opportunity driven by continued whale accumulation and institutional interest. This divergence in sentiment underscores the ongoing debate about Bitcoin's predictable cyclical behavior versus its increasing integration into traditional finance through instruments like IBIT.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending amid ongoing volatility in the Bitcoin ETF market, characterized by recent outflows followed by a modest reversal of inflows. The community remains sharply divided, with some anticipating a prolonged "crypto winter" and further declines, while others maintain a bullish long-term outlook, emphasizing Bitcoin's historical resilience against market fluctuations.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility and increased trading activity as the anticipated FDA decision for its Relacorilant treatment for Cushing's Syndrome approaches. A sharp price decline fuels community fears of potential regulatory hurdles and whispers of a Complete Response Letter, while many longs emphasize the company's robust pipeline and accuse shorts of manipulation, making its near-term outlook a major point of contention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug

FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.

6 Top-Performing ETF Areas of Last Week 

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.

Best-Performing ETFs of November 

November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


Novo Nordisk A/S (NVO) shares slid 3% in the early premarket session on Monday as the Ozempic and Wegovy weight-loss drugmaker snagged a&nbsp;bearish recommendation from a Wall Street firm.&nbsp;Morgan Stanley analyst downgraded&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> to ‘Underweight’ from ‘Equal Weight’ and also reduced the price target for the stock to $47 from $59, the excerpts of the note published by The Fly showed. Morgan Stanley’s updated price target implies a nearly 13% downside from the stock’s Friday close.The stock was among the top five trending equity tickers on Stocktwits early Monday. Retail sentiment toward the stock, however, remained ‘extremely bullish’ (76/100), and the message volume on the stream was ‘high.’<figure class="image"><img style="aspect-ratio:619/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_5_23_05_AM_png_5def6a683f.webp" alt="Screenshot 2025-09-29 at 5.23.05 AM.png" width="619" height="53"><figcaption>NVO sentiment and message volume as of 5:20 a.m. ET, Sept. 29 | source: Stocktwits</figcaption></figure>Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures. According to the firm, this would drive downside revisions to the 2026 and 2027 consensus estimates for Novo Nordisk.&nbsp;Analysts at the firm said the lack of momentum in U.S. prescriptions for Wegovy, Ozempic and Rybelsus makes it cautious on the company's short-term growth profile. Additionally, the analyst noted that the lack of catalysts exacerbates the downside risk profile over the next six months.A New York Times report stated last week that the company was cutting jobs following the profit warning it issued in late July.&nbsp;Novo Nordisk stock has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-analyst-says-i-phone-s-worst-period-in-china-has-passed/chDMvs4R378">Apple Analyst Says ‘iPhone’s Worst Period In China Has Passed’ — The Xiaomi Data That Adds Strength To Bull Case For Cupertino</a>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.

Equity

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.



NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another sales miss for its obesity and diabetes drugs.The company reported Q4&nbsp;earnings per share (EPS) of $5.32, beating the $5.08 consensus estimate, while revenue came in at $13.53 billion, topping Wall Street’s $13.43 billion forecast.&nbsp;Sales of its blockbuster GLP-1 drugs Zepbound and Mounjaro surged but came in slightly below expectations, weighed down by lower realized prices.&nbsp;Mounjaro generated $3.53 billion in revenue, a 60% jump from the prior year but short of analysts’ $3.62 billion estimate. Zepbound posted $1.91 billion in sales, missing the $1.98 billion forecast.&nbsp;This marks the second consecutive quarter where both drugs have fallen short of estimates, according to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html">CNBC</a>.Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.&nbsp;CEO David Ricks called 2024 a highly successful year, highlighting major clinical readouts for tirzepatide in treating chronic diseases tied to obesity, billions in manufacturing expansion, and the launch of Alzheimer’s drug Kisunla and dermatitis medication Ebglyss as key drivers of long-term growth.&nbsp;“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” he added.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Eli_Lilly_sentiment_and_message_volume_Feb_6_premarket_0e4b15d3e8.png" alt="Eli Lilly sentiment and message volume Feb 6 premarket.png" width="1318" height="324"><figcaption>Eli Lilly sentiment and message volume Feb 6 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, Eli Lilly was among the top 10 trending tickers ahead of Thursday’s opening, with sentiment turning more bullish.&nbsp;Optimistic traders pointed to the earnings beat and expected continued strength, with one eyeing a move past $900.&nbsp;<stembedurl>https://stocktwits.com/Zukio/message/603106677</stembedurl>Another said hedge funds and institutional investors would likely drive the&nbsp;actual move during market hours.<stembedurl>https://stocktwits.com/nat9co/message/603108641</stembedurl>For 2025, Eli Lilly expects EPS between $22.50 and $24.00, compared to the $22.69 consensus estimate, and projects revenue between $58 billion and $61 billion, surpassing Wall Street’s $58.91 billion forecast.&nbsp;The company is ramping production to meet soaring demand, estimating it will manufacture at least 1.6 times the number of incretin doses in the first half of 2025 compared to a year ago.&nbsp;Lilly also announced plans to report late-stage data for its next-generation obesity drug retatrutide later this year, ahead of schedule.As of Wednesday’s close, <a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> was up nearly 8% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Eli Lilly &amp; Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6%&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-falls-on-q4-weight-loss-drug-sales/chG8mwrRVc">plunge</a> — the worst session for the stock in nearly four years.&nbsp;The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance, with significant misses in sales for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.However, several Wall Street analysts expressed optimism, suggesting the dip could offer an attractive entry point for investors.Leerink noted Lilly lowered its Q4 revenue guidance by 5% but issued a 2025 revenue forecast 2% above its consensus, according to The Fly. The brokerage maintained its 'Outperform' rating, citing long-term growth potential and a promising pipeline.BofA Securities reiterated a 'Buy' rating with a $997 price target,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/eli-lilly-bofa-says-buy-the-dip-after-shares-slide-on-q4-miss-3813128">according</a> to Investing.com. Analyst Tim Anderson emphasized that despite short-term challenges, Lilly remains a dominant player in the "diabesity" market with significant growth opportunities.JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity, highlighting Lilly's strong 2025 positioning, expanded market presence, and anticipated 60% growth in sellable doses of incretins in the first half of 2025.Mizuho's Jared Holz&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=eli+lilly+mizuho&amp;oq=eli&amp;gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDsyBggCEEUYOzITCAMQLhiDARjHARixAxjRAxiABDIGCAQQRRg5MgYIBRBFGDwyBggGEEUYPDIGCAcQRRg90gEINjAxMGowajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8">told</a> CNBC that "some of the supply commentary from the company makes a lot of sense" and highlighted the nascent stage of the obesity market. However, he flagged valuation as a concern, with Lilly trading at 32 times 2025 earnings estimates—higher than most large-cap pharma peers.Retail message volume on Stocktwits about Lilly jumped over 240% on Tuesday.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_15_premarket_8c6741e2bb.png" alt="LLY sentiment and message volume Jan 15 premarket.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 15 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>Heading into Wednesday, sentiment on the platform remained 'bullish,' as watchers took cues from analyst optimism and kept faith in long-term prospects for Lilly's weight-loss and diabetes drugs remain intact.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly's stock</a> is down 4.5% year-to-date but has gained over 16% in the past 12 months. The company will report fourth-quarter and full-year results next month.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Latest OZEM News

OZEMRoundhill GLP-1 & Weight Loss ETF